<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="153020">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107964</url>
  </required_header>
  <id_info>
    <org_study_id>33794</org_study_id>
    <nct_id>NCT01107964</nct_id>
  </id_info>
  <brief_title>Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome</brief_title>
  <official_title>Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The American Society of Cataract and Refractive Surgery Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline,
      Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical
      markers associated with dry eye disease (Schirmer-1 test values, positive vital staining
      with lissamine green, and fluorescein tear break-up time) when compared to administration of
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Index Score as a measure of subjective symptoms of dry eye</measure>
    <time_frame>45 days post-intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Schirmer-1 test value (mm/5 min) as a measure of tear production</measure>
    <time_frame>45 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lissamine Green staining score as a measure of ocular surface irregularity secondary to dry eye</measure>
    <time_frame>45 days post-intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluorescein tear break-up time (seconds) as a measure of tear film stability</measure>
    <time_frame>45 days post-intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>Omega-3-acid ethyl esters</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Corn oil capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Omega-3-acid ethyl esters</intervention_name>
    <description>1 gram capsule by mouth four times daily for 45 days</description>
    <arm_group_label>Omega-3-acid ethyl esters</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo corn oil capsule</intervention_name>
    <description>1 gram by mouth 4 times daily for 45 days</description>
    <arm_group_label>Corn oil capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Typical symptoms of dry eye (photophobia, burning, foreign body sensation, blurred
             vision improved with blinking)

          -  Schirmer Test &lt; 8 mm/5 minutes

          -  Fluorescein tear break-up time &lt; 8 seconds

          -  No current use of dry eye treatment (except artificial lubrication)

          -  Signature on consent form

        Exclusion Criteria:

          -  Infectious keratoconjunctivitis or inflammatory disease unrelated to dry eye

          -  Eyelid or eyelash abnormalities

          -  Alteration of the nasolacrimal apparatus

          -  Treatment with drugs affecting tearing

          -  Concomitant ocular therapies

          -  Topical ophthalmic steroids taken during the 4 weeks before the study

          -  Pregnant/breast-feeding women

          -  History of liver disease

          -  History of fish and/or shellfish allergy or hypersensitivity

          -  History of corn allergy or hypersensitivity

          -  Treatment with systemic anticoagulation therapy

          -  Patients with bleeding disorders or those receiving anticoagulation (e.g., warfarin,
             enoxaparin, dipyridamole, clopidogrel)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Penn State Hershey Eye Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 19, 2014</lastchanged_date>
  <firstreceived_date>April 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>David Liang</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Dry Eye Syndrome</keyword>
  <keyword>Recent Diagnosis of Dry Eye Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
